2020
Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies
Lee EK, Fader AN, Santin AD, Liu JF. Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies. Gynecologic Oncology 2020, 160: 322-332. PMID: 33160694, DOI: 10.1016/j.ygyno.2020.10.017.Peer-Reviewed Original ResearchConceptsUterine serous carcinomaMolecular featuresDistant recurrenceExtrauterine spreadMultimodality treatmentEndometrial cancerPoor prognosisSerous carcinomaAggressive subtypeClinical managementNovel therapiesFuture therapiesCurrent managementTherapyKey molecular featuresChemotherapySurgeryCarcinomaPrognosisRecurrenceRadiotherapyCancerSubtypesTargeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies.
Erickson BK, Zeybek B, Santin AD, Fader AN. Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies. Current Opinion In Obstetrics & Gynecology 2020, 32: 57-64. PMID: 31833974, PMCID: PMC7307693, DOI: 10.1097/gco.0000000000000599.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, ImmunologicalBiomarkers, TumorCystadenocarcinoma, SerousFemaleHumansMolecular Targeted TherapyRandomized Controlled Trials as TopicReceptor, ErbB-2TrastuzumabUterine NeoplasmsConceptsHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Growth factor receptor 2Uterine serous carcinomaGynecologic malignanciesFactor receptor 2Serous carcinomaReceptor 2Recurrent uterine serous carcinomaAnti-HER2 antibody trastuzumabHER2-positive diseaseAnti-HER2 therapyAnti-HER2 treatmentHER2-positive breastTrial of womenEndometrial cancer subtypesMore treatment optionsEffective therapeutic targetTreatment optionsUterine carcinosarcomaTrastuzumab efficacyHER2 amplificationTargeted therapyGastric cancerSignificant efficacy
2014
Targeted Therapy in Uterine Serous Carcinoma: An Aggressive Variant of Endometrial Cancer
Black JD, English DP, Roque DM, Santin AD. Targeted Therapy in Uterine Serous Carcinoma: An Aggressive Variant of Endometrial Cancer. Women's Health 2014, 10: 45-57. PMID: 24328598, PMCID: PMC3984476, DOI: 10.2217/whe.13.72.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsClass I Phosphatidylinositol 3-KinasesCyclin ECystadenocarcinoma, SerousDrug Resistance, NeoplasmFemaleGenes, erbB-2HumansMolecular Targeted TherapyMutationNeoplasm Recurrence, LocalNeoplasm StagingPhosphatidylinositol 3-KinasesRandomized Controlled Trials as TopicUterine NeoplasmsConceptsUterine serous carcinomaEndometrial cancerAggressive variantSerous carcinomaRecurrent uterine serous carcinomaPIK3CA/AKT/mTORComprehensive surgical stagingRecent whole-exome sequencing studiesHER2/neu geneVaginal cuff brachytherapyNovel therapeutic targetAkt/mTORUSC therapyPaclitaxel chemotherapySurgical stagingBiologic therapyTargeted therapyWhole-exome sequencing studiesTherapeutic targetDriver mutationsTherapyNeu geneCancerGain of functionCarcinoma
2012
Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer
El-Sahwi KS, Schwartz PE, Santin AD. Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer. Expert Review Of Anticancer Therapy 2012, 12: 41-49. PMID: 22149431, PMCID: PMC3287395, DOI: 10.1586/era.11.192.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsClinical Trials, Phase II as TopicCystadenocarcinoma, SerousEndometrial NeoplasmsFemaleHumansMolecular Targeted TherapyNeoplasm Recurrence, LocalRandomized Controlled Trials as TopicUterine NeoplasmsConceptsType II endometrial cancerUterine serous cancerEndometrial cancerSerous cancerAggressive variantType I endometrial cancerFemale genital malignanciesUterine serous carcinomaOlder patientsGenital malignanciesMost recurrencesBetter prognosisSerous carcinomaEndometrial tumorsAggressive subsetEarly diagnosisTherapeutic markersMost carcinomasCancerCarcinomaMarkersHypertensionPostmenopausalObesityPatients
2011
Comparison between 155 cases of robotic vs. 150 cases of open surgical staging for endometrial cancer
ElSahwi KS, Hooper C, De Leon MC, Gallo TN, Ratner E, Silasi DA, Santin AD, Schwartz PE, Rutherford TJ, Azodi M. Comparison between 155 cases of robotic vs. 150 cases of open surgical staging for endometrial cancer. Gynecologic Oncology 2011, 124: 260-264. PMID: 22036203, DOI: 10.1016/j.ygyno.2011.09.038.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overEndometrial NeoplasmsFemaleGynecologic Surgical ProceduresHumansLaparoscopyMiddle AgedMinimally Invasive Surgical ProceduresNeoplasm StagingRandomized Controlled Trials as TopicRoboticsConceptsOpen armsEndometrial cancerSurgical stagingOperative timePara-aortic lymph node dissectionMean lymph node countPre-existing cardiac conditionsRobot-assisted surgical stagingOpen surgical stagingRobotic-assisted stagingLymph node countLymph node dissectionMean hospital stayRetrospective chart reviewBody mass indexPostoperative ileusCardiopulmonary complicationsHospital stayNode dissectionChart reviewBlood lossMass indexMean ageCardiac conditionsRobotic cases